AR061540A1 - ORAL PHARMACEUTICAL COMPOSITION IMPROVED OF AN ACTIVE WATER SOLUBLE AGENT IN WATER - Google Patents
ORAL PHARMACEUTICAL COMPOSITION IMPROVED OF AN ACTIVE WATER SOLUBLE AGENT IN WATERInfo
- Publication number
- AR061540A1 AR061540A1 ARP070102708A AR061540A1 AR 061540 A1 AR061540 A1 AR 061540A1 AR P070102708 A ARP070102708 A AR P070102708A AR 061540 A1 AR061540 A1 AR 061540A1
- Authority
- AR
- Argentina
- Prior art keywords
- weight
- water
- oral pharmaceutical
- pharmaceutical composition
- soluble agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
En la presente se proveen composiciones farmacéuticas orales mejoradas que comprenden por lo menos un agente activo escasamente soluble en agua, preferentemente un inhibidor de ECE (enzima convertidora de endotelinas) y/o un inhibidor de NEP (endopeptidasa neutra), en una cantidad mayor del 10 % peso/peso de la composicion, más preferentemente, comprendiendo el sistema alcalino una mezcla de por lo menos dos compuestos alcalinos en la relacion 1:20 a 20:1, el agente activo es SLV-306 o sus sales, ésteres, hidratos, solvatos, isomeros o derivados, farmacéuticamente aceptables, del mismo; un sistema alcalino en una cantidad superior al 10 % peso/peso de la composicion, que preferentemente comprende una mezcla de por lo menos dos compuestos alcalinos y opcionalmente uno o más excipientes farmacéuticamente aceptables. También se proveen procesos para la preparacion de tales composiciones mejoradas, y métodos para utilizar tales composiciones.Enhanced oral pharmaceutical compositions are provided herein comprising at least one water-poorly active agent, preferably an ECE inhibitor (endothelin converting enzyme) and / or an NEP inhibitor (neutral endopeptidase), in an amount greater than 10% weight / weight of the composition, more preferably, the alkaline system comprising a mixture of at least two alkaline compounds in the ratio 1:20 to 20: 1, the active agent is SLV-306 or its salts, esters, hydrates , solvates, isomers or pharmaceutically acceptable derivatives thereof; an alkaline system in an amount greater than 10% weight / weight of the composition, which preferably comprises a mixture of at least two alkaline compounds and optionally one or more pharmaceutically acceptable excipients. Processes for the preparation of such improved compositions, and methods for using such compositions are also provided.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06115881 | 2006-06-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR061540A1 true AR061540A1 (en) | 2008-09-03 |
Family
ID=37327215
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070102708 AR061540A1 (en) | 2006-06-22 | 2007-06-20 | ORAL PHARMACEUTICAL COMPOSITION IMPROVED OF AN ACTIVE WATER SOLUBLE AGENT IN WATER |
Country Status (4)
| Country | Link |
|---|---|
| CN (1) | CN101511344A (en) |
| AR (1) | AR061540A1 (en) |
| MX (1) | MX2008016418A (en) |
| TW (1) | TW200808356A (en) |
-
2007
- 2007-06-20 AR ARP070102708 patent/AR061540A1/en not_active Application Discontinuation
- 2007-06-21 TW TW96122260A patent/TW200808356A/en unknown
- 2007-06-21 CN CNA2007800234341A patent/CN101511344A/en active Pending
- 2007-06-21 MX MX2008016418A patent/MX2008016418A/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| TW200808356A (en) | 2008-02-16 |
| CN101511344A (en) | 2009-08-19 |
| MX2008016418A (en) | 2009-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2606342T3 (en) | Compositions for oral care of stannous salt and sodium tripoli phosphate and methods | |
| AR061289A1 (en) | STABILIZED PHARMACEUTICAL COMPOSITIONS THAT INCLUDE FESOTERODINE | |
| ECSP109905A (en) | 7 TYPE TOLL RECEIVER MODULATORS | |
| NO20082744L (en) | Oral pharmaceutical dosage form comprising as active ingredients a proton pump inhibitor together with acetylsalicylic acid | |
| BR112012018384A2 (en) | solid pharmaceutical composition with enhancers and methods of preparation thereof. | |
| WO2013016697A3 (en) | 17-hydroxyprogesterone ester-containing oral compositions and related methods | |
| AR055090A1 (en) | A PHARMACEUTICAL PRESENTATION OF A MODIFIED LIBERATION DOSAGE FORM INCLUDING AN INHIBITOR OF THE CYCLOOXYGENASE ENZYME | |
| AR073123A1 (en) | PHARMACEUTICAL COMPOSITION INCLUDING A SUBSTANTIALLY AMORFO TAXANE TO BE USED IN THE TREATMENT OF NEOPLASIC DISEASE | |
| AR062980A1 (en) | PHARMACEUTICAL COMPOSITIONS OF PIRIMIDIL-AMINO-BENZAMIDA COMPOUNDS | |
| AR072261A1 (en) | PIPERAZIN-PIRAZOLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEMSELVES AND USES OF THE SAME AS ANTICANCERIGEN AGENTS. | |
| BR112013004455A2 (en) | compositions for gastric delivery of active agents | |
| PE20071310A1 (en) | LIQUID PHENYLEPHRINE FORMULATIONS | |
| RS53209B (en) | Pharmaceutical composition for a hepatitis c viral protease inhibitor | |
| UY27320A1 (en) | NEW PHARMACEUTICAL COMPOSITIONS | |
| RS51563B (en) | Pharmaceutical compositions containing rosuvastatin calcium | |
| NZ598839A (en) | Stabilized liquid and lyophilized adamts13 formulations | |
| ATE493973T1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING IRBESARTAN | |
| BRPI0606606A2 (en) | stable prostaglandin-containing compositions | |
| CY1108700T1 (en) | DRUG ALPHA-HYDROXIC ACID RELEASE COMPOSITIONS AND METHODS OF USE | |
| PE20091949A1 (en) | SOLID PHARMACEUTICAL FORMULATION WITH DELAYED RELEASE | |
| CL2013002234A1 (en) | Use of a pharmaceutical composition comprising at least one prostacyclin or an analogue thereof selected from treprostinil, ilorpost, cicaprost or beraprost, and at least one phosphodiesterase 4 (pde4) inhibitor, because it serves in the prevention or treatment of cystic fibrosis . | |
| AR066905A1 (en) | INTRANASAL ADMINISTRATION OF ASENAPINE AND CORRESPONDING PHARMACEUTICAL COMPOSITIONS | |
| AR076864A1 (en) | PROCEDURE AND COMPOSITION TO IMPROVE THE ABSORPTION OF THERAPEUTIC AGENTS | |
| NO20083555L (en) | Compositions comprising desmopressin | |
| ES2535106T3 (en) | Pharmaceutical compositions of calcium rosuvastatin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |